p22phox (E7Y1F) XP® Rabbit mAb #37570
- WB
- IHC
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 22 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:500 - 1:2000 |
| Immunofluorescence (Frozen) | 1:50 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:800 - 1:3200 |
Storage
Protocol
Specificity / Sensitivity
p22phox (E7Y1F) XP® Rabbit mAb recognizes endogenous levels of total p22phox protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro187 of human p22phox protein.
Background
The p22phox protein is a critical component of the membrane-bound NADPH Oxidase of phagocytes that generate superoxide anion and alter the redox states in cells. p22phox associates with the catalytic subunit gp91phox (NOX2), NOX1, NOX3, or NOX4 to form the active NADPH Oxidase. The enzymatic complex includes cytosolic subunits p40phox, p47phox, p67phox, and Rac2 that are recruited to the membrane-bound subunits, subsequently generating superoxide anion as the final product, serving as a microbial killing system (1,2). Multiple phosphorylation sites in each subunit of these oxidases potentiate its activation, including the phosphorylation of p22phox at Thr147 epitope facing the cytoplasmic space (3-5). NADPH Oxidase is associated with several diseases, including hyperglycemia, cancer, inflammation and vascular cases, as well as neurodegenerative diseases (6), including its activation by SOD1 mutants in Amyotrophic Lateral Sclerosis (7), and in Alzheimer's disease where NADPH Oxidase activation exacerbates the effects of fibrillary tangles and β-amyloid plaques, causing neuronal death (8,9).
- Nauseef, W.M. (2019) Curr Opin Immunol 60, 130-140.
- Brandes, R.P. et al. (2014) Free Radic Biol Med 76, 208-26.
- Belambri, S.A. et al. (2018) Eur J Clin Invest 48 Suppl 2, e12951.
- Lewis, E.M. et al. (2010) J Biol Chem 285, 2959-67.
- Boillée, S. and Cleveland, D.W. (2008) J Clin Invest 118, 474-8.
- Rastogi, R. et al. (2016) Front Cell Neurosci 10, 301.
- Shiose, A. and Sumimoto, H. (2000) J Biol Chem 275, 13793-801.
- Bianca, V.D. et al. (1999) J Biol Chem 274, 15493-9.
- Chay, K.O. et al. (2017) Chonnam Med J 53, 196-202.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.